GYL Financial Synergies LLC Purchases New Position in GlaxoSmithKline plc (NYSE:GSK)

GYL Financial Synergies LLC purchased a new position in shares of GlaxoSmithKline plc (NYSE:GSK) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 43,706 shares of the pharmaceutical company’s stock, valued at approximately $1,826,000.

Several other hedge funds have also recently added to or reduced their stakes in GSK. Boston Partners purchased a new position in shares of GlaxoSmithKline during the 4th quarter worth about $65,234,000. Norges Bank purchased a new stake in GlaxoSmithKline in the 4th quarter valued at about $17,275,000. Two Sigma Investments LP purchased a new stake in GlaxoSmithKline in the 4th quarter valued at about $15,936,000. Deutsche Bank AG boosted its position in GlaxoSmithKline by 221.0% in the 4th quarter. Deutsche Bank AG now owns 529,309 shares of the pharmaceutical company’s stock valued at $20,222,000 after buying an additional 364,431 shares during the period. Finally, Millennium Management LLC boosted its position in GlaxoSmithKline by 612.0% in the 4th quarter. Millennium Management LLC now owns 365,325 shares of the pharmaceutical company’s stock valued at $13,959,000 after buying an additional 314,016 shares during the period. 11.26% of the stock is owned by hedge funds and other institutional investors.

Shares of GSK traded up $0.39 during mid-day trading on Wednesday, hitting $40.31. The company’s stock had a trading volume of 96,189 shares, compared to its average volume of 2,687,354. GlaxoSmithKline plc has a 52-week low of $36.41 and a 52-week high of $42.36. The stock has a market capitalization of $99.91 billion, a PE ratio of 12.77, a PEG ratio of 2.07 and a beta of 0.74. The company has a debt-to-equity ratio of 6.92, a quick ratio of 0.48 and a current ratio of 0.72.

GlaxoSmithKline (NYSE:GSK) last announced its quarterly earnings results on Wednesday, May 1st. The pharmaceutical company reported $0.79 earnings per share for the quarter, topping the consensus estimate of $0.66 by $0.13. GlaxoSmithKline had a net margin of 12.27% and a return on equity of 157.04%. The firm had revenue of $9.98 billion during the quarter, compared to analysts’ expectations of $9.86 billion. Equities research analysts forecast that GlaxoSmithKline plc will post 2.91 EPS for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Thursday, July 11th. Stockholders of record on Friday, May 17th will be given a $0.4953 dividend. The ex-dividend date of this dividend is Thursday, May 16th. This represents a $1.98 annualized dividend and a dividend yield of 4.92%. GlaxoSmithKline’s payout ratio is presently 61.71%.

Several equities research analysts have issued reports on GSK shares. UBS Group cut shares of GlaxoSmithKline from a “buy” rating to a “neutral” rating in a research report on Friday, February 22nd. Zacks Investment Research raised shares of GlaxoSmithKline from a “hold” rating to a “buy” rating and set a $44.00 price objective for the company in a research report on Tuesday, April 23rd. Cowen reissued a “hold” rating and issued a $45.00 price objective on shares of GlaxoSmithKline in a research report on Monday. Finally, Shore Capital cut shares of GlaxoSmithKline from a “buy” rating to a “hold” rating in a research report on Friday, March 8th. One analyst has rated the stock with a sell rating, sixteen have issued a hold rating and four have given a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $42.28.

In other GlaxoSmithKline news, Director Plc Glaxosmithkline purchased 385,714 shares of the stock in a transaction dated Tuesday, May 28th. The stock was purchased at an average price of $14.00 per share, with a total value of $5,399,996.00. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. 10.00% of the stock is currently owned by corporate insiders.

TRADEMARK VIOLATION WARNING: “GYL Financial Synergies LLC Purchases New Position in GlaxoSmithKline plc (NYSE:GSK)” was first posted by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this article on another website, it was stolen and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this article can be accessed at https://sportsperspectives.com/2019/06/12/gyl-financial-synergies-llc-purchases-new-position-in-glaxosmithkline-plc-nysegsk.html.

About GlaxoSmithKline

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.

Featured Article: What are momentum indicators and what do they show?

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline plc (NYSE:GSK).

Institutional Ownership by Quarter for GlaxoSmithKline (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.